Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Radium-223 label change

Bertrand Tombal • 2 Jun 2019
ASCO 2019
Genitourinary Cancer Prostate Cancer Abiraterone Radium-223

Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium give his opinion on the European Medicines Agency’s (EMA) change to the label for Radium-223 for the treatment of metastatic castration-resistant prostate cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Bertrand Tombal

1:24
PSA limitations in prostate cancer: advancing treatment de-escalation with imaging biomarkers
Bertrand Tombal • 5 Dec 2023
2:54
Time for treatment de-escalation for mHSPC?
Bertrand Tombal • 5 Jan 2024
2:43
Optimizing PSA recurrence treatment
Bertrand Tombal • 5 Dec 2023
2:10
PSA rise factors & significance of doubling time
Bertrand Tombal • 5 Dec 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals